WHP Starts Construction of Oxford BioMedica Viral Vector Manufacturing Facility
An existing building is being converted into Oxford BioMedica’s new facility.
Multi-disciplinary engineering company WHP has secured the design, construction, and project management contract for the development of a new viral vector manufacturing center for gene and cell therapy company Oxford BioMedica, WHP said in a Feb. 21, 2019 press release. Construction has started on the new facility, which is being established in a former Royal Mail sorting office in Oxford, UK. Phases 1 and 2 of the expansion comprise the conversion of the building into GMP cleanroom suites and fill-and-finish production areas, as well as offices, warehousing, and quality control laboratories.
WHP is responsible for the design and build, including testing and validation. The design includes a full, three-dimensional building information model, including cleanroom architecture; heating, ventilation, and air conditioning (HVAC); mechanical and electrical systems; and process and critical utilities systems.
The areas have been designed in full compliance with Medicines and Healthcare Products Regulatory Agency regulations and conform to ISO cleanroom standards. This design includes the use of zoned HVAC systems to maintain segregation, cleanliness, air pressures, and other environmental controls.
WHP previously designed and installed the original pilot plant for theLentiVector delivery platform at Oxford Biomedica’s Yarnton premises in 2015.
Oxford Biomedica announced the expansion of its manufacturing capacity to create the 82,398-ft2facility near its headquarters in Oxford in a Sept. 13, 2018 press release. Once open, the facility will more than double the group’s bioprocessing capacity. The plan is to open the new offices and warehouse in the first quarter (Q1) of 2019, with the additional GMP suites being ready in Q1 2020. This new facility will create up to 100 new, highly skilled positions over the next two years.
Sources: WHP, Oxford Biomedica
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
